To the Editor: It is with great interest that we read the article of Atkins et al. (1) and the accompanying commentary of Panelli et al. (2) about the possible usefulness of carbonic anhydrase IX-G250MN (CAIX) expression as a biomarker to predict responses to interleukin-2 therapy in renal cell carcinoma. Atkins et al. (1) showed that high-positively CAIX staining [according to Bui et al. (3) ] of mostly primary renal cell carcinoma tumors correlated with a significantly better survival rate after interleukin-2 therapy. This is strikingly in line with a previous observation in a study in which we compared the usefulness of the diagnostic imaging modalities Although their data support the contention that low CAIXexpressing tumors are associated with poor prognosis, it is premature to link their results too closely with those reported in our study. For example, the G250 antibody used in their imaging study binds to a different epitope on CAIX than the MN75 antibody used in the University of California at Los Angeles and Dana Farber-Harvard Cancer Center Renal Cancer Program immunohistochemical studies. To date, no data exist that support a relationship between tissue G250 binding and either prognosis or response to interleukin-2 (IL-2) therapy. Furthermore, whereas data with the MN75 antibody relate high CAIX expression on the primary tumor specimen with subsequent response or survival in patients receiving IL-2 therapy, insufficient information is available to determine whether such a relationship would persist if exclusively metastatic lesions were evaluated as proposed with the imaging studies. Nonetheless, the investigators raise several intriguing points about the complementary information that could potentially be obtained through their imaging technique. Such information, if validated, may help to better dissect out the mechanisms of tumor response and resistance to IL-2-based immunotherapy and potentially other novel treatments currently under investigation in patients with advanced renal cancer. My coauthors and I agree that further exploration in the context of clinical trials is warranted. 
